3-((2-chloropyridin-4-yl)oxy)-2-ethyl-6-methylpyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-((2-chloropyridin-4-yl)oxy)-2-ethyl-6-methylpyridine
• 英文别名: 3-[(2-Chloro-4-pyridinyl)oxy]-2-ethyl-6-methylpyridine；3-(2-chloropyridin-4-yl)oxy-2-ethyl-6-methylpyridine
• 化学式: C₁₃H₁₃ClN₂O
• 分子量: 248.712
• InChiKey: YABSIOWOJJSLHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-二氯吡啶 、 2-乙基-6-甲基-3-羟基吡啶 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 3-((2-chloropyridin-4-yl)oxy)-2-ethyl-6-methylpyridine
  参考文献：
  名称：

  WO2020139636A5

  摘要：

  公开号：

  WO2020139636A5

文献信息

• (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Nexys Therapeutics, Inc.

  公开号：US20220054465A1

  公开（公告）日：2022-02-24

  The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with TGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.
• [EN] (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE (PYRIDIN-2-YL)AMINE UTILISÉS COMME INHIBITEURS DE TGF-BÊTA R1 (ALK5) POUR LE TRAITEMENT DU CANCER
  申请人：NEXYS THERAPEUTICS INC

  公开号：WO2020139636A1

  公开（公告）日：2020-07-02

  The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.
• WO2020139636A5
  申请人：——

  公开号：WO2020139636A5

  公开（公告）日：2022-12-16